文献速递造血干细胞移植与细胞治疗淋巴瘤浆细胞疾病

三十年间自体血液或骨髓移植后晚期死亡率和预期寿命的趋势:BMTSS报告

Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report.
PubMed 文献 · J Clin Oncol · 2022-03-09

该研究基于BMT幸存者研究构建了4702例接受自体血液或骨髓移植的血液肿瘤患者队列,随访至2021年4月19日。结果显示自体移植受者预期寿命减少7年,5年全因死亡调整风险随年代推移而下降,感染和后续肿瘤相关晚期死亡减少,但心血管和肾脏疾病相关死亡未见下降。

要点

  • 自体移植受者预期寿命减少7年。
  • 5年全因死亡调整风险随移植年代推移而下降。
  • 感染和后续肿瘤相关晚期死亡下降,心血管和肾脏疾病相关死亡未下降。

核心结论

  • 自体血液或骨髓移植受者的晚期死亡率在30年间有所下降,但仍需持续努力减少感染、后续肿瘤以及心血管和肾脏疾病的发生以进一步降低晚期死亡率。

研究设计与样本

  • 利用BMT幸存者研究构建队列,纳入1981年至2014年在三个移植中心接受自体血液或骨髓移植且移植后生存≥2年的4702例血液肿瘤患者,随访截至2021年4月19日。

主要发现

  • 移植时中位年龄53岁(范围0-78岁),58.7%为男性,67.8%为非西班牙裔白人,28.3%在2011至2014年间接受移植。
  • 自体移植受者预期寿命减少7年。
  • 5年全因死亡调整风险随年代推移下降:以1981-1999为参照,2000-2005年HR=0.77(95%CI 0.62-0.94),2006-2010年HR=0.64(95%CI 0.51-0.79),2011-2014年HR=0.56(95%CI 0.45-0.71),Ptrend<.001;生命损失年数从5.0年降至1.6年。
  • 全因死亡率下降在因霍奇金淋巴瘤或浆细胞疾病接受移植者中最为明显,但在因非霍奇金淋巴瘤接受移植者或接受全身照射预处理者中未观察到。
  • 感染相关晚期死亡下降(Ptrend<.0001,主要见于2006年之前的移植)和后续肿瘤相关晚期死亡下降(Ptrend=.03,仅限于治疗相关髓系肿瘤相关死亡的下降),但心血管或肾脏疾病相关死亡未下降。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We determined trends in life expectancy and cause-specific late mortality after autologous blood or marrow transplantation (BMT) performed over a 30-year period, using the BMT Survivor Study. METHODS: We constructed a cohort of 4,702 individuals with hematologic neoplasms who lived ≥ 2 years after autologous BMT performed between 1981 and 2014 at three transplant centers. The end of follow-up was April 19, 2021. The primary exposure variable was autologous BMT performed in four eras: 1981-1999; 2000-2005; 2006-2010; and 2011-2014. Vital status and cause of death were obtained from National Death Index Plus program and Accurinct databases. RESULTS: The median age at BMT was 53 years (range, 0-78 years), 58.7% were male, 67.8% were non-Hispanic White, and 28.3% had undergone transplantation between 2011 and 2014. Autologous BMT recipients experienced a 7-year reduction in life expectancy. The adjusted hazard of 5-year all-cause mortality declined over the four eras (reference: 1981-1999; hazard ratio [HR]2000-2005 = 0.77; 95% CI, 0.62 to 0.94; HR2006-2010 = 0.64; 95% CI, 0.51 to 0.79; HR2011-2014 = 0.56; 95% CI, 0.45 to 0.71; Ptrend < .001), as did years of life lost (5.0 years to 1.6 years). The reduction in all-cause mortality was most pronounced among those transplanted for Hodgkin lymphoma or plasma cell dyscrasias, but was not observed among those transplanted for non-Hodgkin lymphoma or those conditioned with total-body irradiation. We also observed a decline in late deaths because of infection (Ptrend < .0001; primarily for BMTs before 2006) and subsequent neoplasms (Ptrend = .03; confined to decline in therapy-related myeloid neoplasm-related mortality) but not because of cardiovascular or renal disease. CONCLUSION: Late mortality among autologous BMT recipients has declined over a 30-year period. However, ongoing efforts are needed to mitigate development of infections, subsequent neoplasms, and cardiovascular and renal disease to further reduce late mortality.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bhatia S, Dai C, Landier W, et al. Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report. J Clin Oncol. 2022. PMID: 35263165. doi:10.1200/JCO.21.02372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。